Speratum Biopharma develops a new class of RNA interference (RNAi) therapeutics designed to inhibit dysregulated cellular pathways driving cancer. Utilizing the proprietary NoPass™ platform for intelligent RNAi design and the Nano-In™ delivery system, the company achieves targeted, multi-pathway control over oncogenic processes. Their flagship candidate, NM-198, aims to provide safer and more effective precision oncology solutions for aggressive malignancies.
Funding
Funding not disclosed
Founders
Product
Problem
Many solid tumors lack effective treatment options due to challenges in delivering therapeutics directly to the tumor site and the limited ability of current drugs to inhibit tumor growth effectively. Systemic delivery of therapeutics often results in off-target effects and insufficient drug concentrations within the tumor microenvironment.
Solution
Speratum Biopharma is developing targeted molecular therapeutics based on a proprietary RNA interference (RNAi) mimic of miR-198, a naturally occurring microRNA involved in the pathogenesis of several solid cancers. The company's technology combines this RNAi mimic with a novel biocompatible material designed for systemic and targeted delivery of nucleic acids. This approach aims to enhance the delivery of oligonucleotides directly to the tumor, inhibiting tumor growth while minimizing off-target effects. The multi-component therapeutic is designed to address multiple cancer types.
Target Audience
The primary target audience includes patients with solid tumors who are in need of more effective and targeted treatment options.
Features
- Proprietary RNAi mimic of miR-198 for targeted tumor suppression
- Novel biocompatible material for systemic and targeted delivery of nucleic acids
- Multi-component therapeutic approach targeting multiple cancer types
- Technology platform exclusively licensed from Baylor College of Medicine